Bliss GVS Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of 0.50 per equity share.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's board met on May 12, 2025 and approved audited results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion. On a standalone basis, revenue from operations grew ~10% to Rs. 66,720 lakh and net profit jumped ~36% to Rs. 6,897 lakh (helped by the absence of last year's Rs. 4,109 lakh exceptional impairment). Consolidated revenue rose ~5% to Rs. 80,973 lakh and net profit grew ~11% to Rs. 9,026 lakh. The board recommended a final dividend of Rs. 0.50 per share (50% on Rs. 1 face value), subject to shareholder approval at the 40th AGM on July 31, 2025. The company also approved the sale of its 51% step-down subsidiary Greenlife Bliss Healthcare (Nigeria) to the existing non-controlling shareholder for USD 1.3 million, issuance of up to 12.1 lakh sweat equity shares to the MD and a Vice President, and re-appointment of BDO India as internal auditor.
For shareholders: a modest final dividend and strong standalone profit growth, partly due to last year's one-time impairment not repeating. Dilution risk from sweat equity to the MD and VP, and ongoing restructuring of African subsidiaries, are the key points to watch.